Endo will book a pretax, noncash charge of $625M for Q1, taking the liability accrual for the lawsuits to $1.1B. Endo had previously provisioned $520M.
The deal adds to the $54.4M that Endo agreed to pay last year to resolve other cases. Peer device-makers have been facing similar claims as well, including J&J and Boston Scientific.
Endo is due to release its results this morning.